LT-3001 is under clinical development by Lumosa Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect LT-3001’s likelihood of approval (LoA) and phase transition for Acute Ischemic Stroke took place on 05 Aug 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LT-3001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

LT-3001 overview

LT-3001 is under development for the treatment of acute ischemic stroke. The drug candidate is a new chemical entity which is composed of a short polypeptide with restoring cerebral blood flow function and a small molecule moiety. It is administered through intravenous route. It is a synthetic small pseudopeptide developed by combining a free radical scavenger.

Lumosa Therapeutics overview

Lumosa Therapeutics is a clinical-stage pharmaceutical company. It develops novel drugs for the treatment of neurological and inflammatory diseases. The company’s products pipeline includes LT-1001 (Naldebain), a long-acting analgesic injection that contains a prodrug of nalbuphine to treat post-operative pain; LT-3001, a novel small molecule to treat acute ischemic stroke; LT-2003, a dual-functional protein drug to treat cancer; and LT-5001, a topical drug to treat uremic pruritus. It also provides translational research and licensing assessment services. The company collaborates with biotech and pharmaceutical companies for product licensing, development and commercialization. Lumosa Therapeutics is headquartered in Taipei, Taiwan.

Quick View LT-3001 LOA Data

Report Segments
  • Innovator
Drug Name
  • LT-3001
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.